Evidence map›Paper›PMID 37740070›Full record

ArticleInternational journal of clinical oncology2023

Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group.

Shigemitsu Horie, Sei Naito, Shingo Hatakeyama, Shuya Kandori, Kazuyuki Numakura, Renpei Kato, Tomoyuki Koguchi, Shingo Myoen, Yoshihide Kawasaki, Akihiro Ito and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shigemitsu HorieDepartment of Urology, Faculty of Medicine, Yamagata University, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan.
Sei NaitoDepartment of Urology, Faculty of Medicine, Yamagata University, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan. seinaito@med.id.yamagta-u.ac.jp.ORCID http://orcid.org/0000-0002-6104-4344
Shingo HatakeyamaDepartment of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan.
Shuya KandoriDepartment of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.
Kazuyuki NumakuraDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Renpei KatoDepartment of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan.
Tomoyuki KoguchiDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Shingo MyoenDepartment of Urology, Miyagi Cancer Center, 47-1 Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan.
Yoshihide KawasakiDepartment of Urology, Tohoku University School of Medicine, 1-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan.
Akihiro ItoDepartment of Urology, Tohoku University School of Medicine, 1-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan.
Hisanobu AdachiDepartment of Urology, Miyagi Cancer Center, 47-1 Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan.
Yoshiyuki KojimaDepartment of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Wataru ObaraDepartment of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan.
Tomonori HabuchiDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Hiroyuki NishiyamaDepartment of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan.
Norihiko TsuchiyaDepartment of Urology, Faculty of Medicine, Yamagata University, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC).

methodsA database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018. Using univariable and multivariable analyses, we retrospectively analyzed disease-free survival (DFS) and overall survival (OS) in this database, constructed a new prognostic model according to these results, and estimated the model fit using c-index on the new and mIMDC models.

resultsIndependent poorer prognostic factors for both DFS and OS include the following: ≥ 1 Eastern Cooperative Oncology Group performance status, 2.0 mg/dL C-reactive protein, and > upper normal limit of white blood cell count. The median DFS in the favorable (no factor), intermediate (one factor), and poor-risk group (two or three factors) was 76.1, 14.3, and 4.0 months, respectively (P < 0.001). The 3-year OS in the favorable, intermediate, and poor-risk group were 92%, 44%, and 0%, respectively (P < 0.001). The c-indices of the new and mIMDC models were 0.67 and 0.60 for DFS (P = 0.060) and 0.74 and 0.63 for OS (P = 0.012), respectively.

conclusionThe new preoperative prognostic model in LLRCC can be used in patient care and clinical trials.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansJapanNephrectomyPrognosisRetrospective StudiesLocalized and locally advanced renal cell carcinomaNephrectomyOverall survivalPrognostic modelRecurrence-free survivalRenal cell carcinoma

Identifiers

PMID37740070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.